5th Nov 2008 07:00
Sinclair Pharma plc Sinclair Announces Appointment of Vice President of Business Development for North America & South Pacific
5 November 2008, Godalming, UK: Sinclair Pharma plc ("Sinclair": SPH:L), the international specialty pharma company, is pleased to announce the appointment of Dr Ross Macdonald as Vice President of Business Development for North America & South Pacific reporting to Marco Mastrodonato, Executive Vice President.
Dr Macdonald has over 20 years of experience in the pharmaceutical industry with extensive knowledge of the dermatology field, both in the USA and throughout the world. He joins Sinclair from Stiefel Laboratories, Inc where he was most recently Vice President, Corporate Development progressing from his role as Vice President Business Development with Connetics Corporation when that company was acquired by Stiefel.
Prior to this Dr Macdonald held the post of Vice President of Research & Development with F.H. Faulding & Co. Limited, an Australian pharmaceutical and healthcare company and was the former Managing Director of Soltec Research, where he led that company's emphasis on dermatology and established its many successful commercial relationships with dermatology companies worldwide. Dr Macdonald has a Ph.D. in biochemistry from Monash University and a postgraduate diploma from the Business School of Swinburne University in Australia.
In his new role, Dr Macdonald will be primarily responsible for developing new commercial opportunities for Sinclair with a particular focus on dermatology products.
Dr Michael Flynn, CEO of Sinclair commented:
"I am very pleased to welcome Dr Ross Macdonald aboard as Vice President Business Development North America & South Pacific."
"Ross has an excellent track record of success combined with extensive experience in the pharmaceutical industry and knowledge of dermatology. I believe this experience and focus on North America and the South Pacific willfurther reinforce Sinclair's internal capabilities and be tremendously valuable for generating growth within this important region."
- ends -
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Mariyam Rawat, Communications & Investor relations [email protected]
Capital MS&L
Mary Clark, Anna Mitchell Tel +44 (0)20 7307 5340
Notes to Editors:
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries.
Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. The company focuses on niche therapeutic areas and its current portfolio includes products for a wide range of dermatological conditions and oral health.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
vendorRelated Shares:
Sinclair Pharma